STOCK TITAN
  1. Home
  2. News
  3. TWST

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.

The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.

Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.

For more information, please visit Twist Bioscience.

News

Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 50,000 restricted stock units and 70,000 shares to its chief financial officer, Adam Laponis, as an inducement material to his acceptance of employment with Twist. The RSUs vest quarterly over a 48-month period, with the first 25% vesting on the one-year anniversary of Mr. Laponis' employment. The shares subject to the executive compensation programs include RSUs and performance stock units that vest based on achievement against established metrics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
News

Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

Rhea-AI Summary
Twist Bioscience Corporation (TWST) appoints Adam Laponis as chief financial officer. Mr. Laponis brings extensive experience from Eargo, Inc., Tesla, Inc., and Cardinal Health, with a track record of driving profitable growth and increasing revenue. His appointment is expected to drive value for stakeholders and contribute to the company's growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
management
-
News

Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8. The presentation will be webcast live and can be accessed through the company's investor relations section. A replay will be archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
News

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results

Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $245.1 million in Fiscal 2023, a 20% increase over 2022. Orders also grew to $264 million, up 17% from 2022. Fiscal 2024 revenue is expected to range between $285 million to $290 million. The company's CEO, Dr. Emily M. Leproust, expressed optimism for the future, focusing on profitability and growth for the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.9%
Tags
earnings
-
News

Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service

Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) Launches Twist Express Genes, a new gene synthesis service with a turnaround time of five to seven business days. The service is enabled by the state-of-the-art Wilsonville manufacturing facility, offering high-quality synthetic DNA using its silicon platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.96%
Tags
none
-
News

Twist Bioscience to Present at 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces participation in the 6th Annual Evercore ISI HealthCONx Conference. CEO Emily M. Leproust and CFO Jim Thorburn will engage in a fireside chat on November 28 at 7:30 a.m. Eastern Time in Miami, FL. The webcast will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
News

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces grant of 130,400 restricted stock units to 15 new hires. The RSUs vest over a 48-month period, in accordance with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
none
-
News

Twist Bioscience to Report Fiscal 2023 Fourth Quarter and Full Year Financial Results on Friday, November 17, 2023

Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will release its financial results for the fiscal 2023 fourth quarter and full year on November 17, 2023. The company will hold a conference call and live webcast at 8:00 a.m. Eastern Time to discuss the results and provide a business update. The press release and webcast will be accessible from the company's website. Telephone participants must register in advance to receive the dial-in number and PIN. Webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
conferences earnings
-
News

Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing

Rhea-AI Summary
Twist Bioscience launches Twist Full Length Unique Dual Index Adapters for PCR-free whole genome sequencing and multiplexing. The adapters streamline library preparation, reduce hands-on time, and eliminate PCR-related errors. They come with 1536 barcoded indexes for tracking individual samples, allowing researchers to run up to 1536 samples in a single sequencing run. Twist will showcase the new offering at the ASHG 2023 conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
none
News

Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million

Rhea-AI Summary
Twist Bioscience announces antibody discovery agreement with Bayer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $37.11 as of March 3, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.2B.

What does Twist Bioscience Corporation do?

Twist Bioscience specializes in synthetic DNA production, utilizing a proprietary semiconductor-based platform to create high-quality DNA efficiently.

How does Twist Bioscience's technology differ from traditional methods?

Twist Bioscience uses a 10,000-well silicon platform instead of traditional 96-well plastic plates, offering faster, cost-effective, and high-throughput DNA synthesis.

What are some applications of Twist Bioscience's synthetic DNA?

Applications include personalized medicine, sustainable chemical production, improved agriculture, in vivo diagnostics, biodetection, and data storage.

Where does Twist Bioscience generate most of its revenue?

Twist Bioscience primarily generates its revenue from the United States.

How does Twist Bioscience contribute to personalized medicine?

By providing rapid and high-quality DNA synthesis, Twist Bioscience accelerates the development of personalized medical treatments.

What is the significance of using silicon in DNA synthesis?

Using silicon allows Twist Bioscience to overcome inefficiencies in traditional DNA production, enabling faster and more cost-effective synthesis.

Can Twist Bioscience's technology be used in agriculture?

Yes, the synthetic DNA tools can improve agricultural production by enabling the development of better crops and agricultural methods.

What ongoing projects does Twist Bioscience have?

Twist Bioscience is involved in various projects across personalized medicine, sustainable chemical production, and new applications such as in vivo diagnostics and data storage.

How does Twist Bioscience's platform support researchers?

The platform provides researchers with high-throughput, high-quality synthetic DNA, enabling them to quickly explore and develop new opportunities.

Where can I find more information about Twist Bioscience?

Additional information is available on their official website: www.twistbioscience.com.
Stock TWST logo
Twist Bioscience

Nasdaq:TWST

TWST Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

TWST Stock Data

2.23B
58.35M
1.94%
110.12%
15.4%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO